PubRank

Christine Solbach

Author PubWeight™ 39.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2009 7.21
2 Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012 4.24
3 Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002 2.67
4 A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011 2.26
5 T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009 2.26
6 A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012 1.83
7 HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003 1.59
8 Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat 2011 1.53
9 Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002 1.48
10 Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat 2009 1.38
11 Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer 2011 1.16
12 Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 2007 1.07
13 Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003 1.05
14 HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013 1.04
15 Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One 2011 1.03
16 The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 2005 1.00
17 Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer 2012 0.97
18 Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis. Eur J Cancer 2008 0.96
19 Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011 0.94
20 Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep 2004 0.92
21 Evaluation of the stereotactic 8G vacuum-assisted breast biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV). Invest Radiol 2005 0.89
22 Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 2012 0.87
23 Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol 2014 0.85
24 EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 2004 0.82
25 Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Appl Immunohistochem Mol Morphol 2005 0.80
26 Acute ethanol intoxication during pregnancy and consecutive fetal cardiac arrest: a case report. J Perinat Med 2003 0.75
27 EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Adv Otorhinolaryngol 2005 0.75
28 Value of electrical impedance scanning (EIS) in the evaluation of BI-RADS III/IV/V-lesions. Technol Cancer Res Treat 2005 0.75